Bavarian Nordic A/s

Aventis Research & Technologies Gmbh & Co Kg

Kay Brinkmann

Robin Steigerwald

Jürgen Hausmann

Karen Baur

Paul Chaplin

Thomas Kiy

Ulrike Dirmeier

Juergen Hausmann

The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof. The invention is drawn to compositions and methods for the induction of strong CD8 T cell and antibody responses to a specific antigen(s) by administering one or more immunizations of the recombinant MVA to a mammal, preferably a human.

PR13.5 promoter for robust T-cell and antibody responses

The invention is drawn to compositions and methods for the induction of an immune response, in particular a strong CD8 T cell response, to a specific antigenic determinant without raising a significant antibody response to the antigenic determinant after a first, priming immunization. The method comprises administering to the host a recombinant poxviral vector comprising a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The recombinant poxviral vector comprises a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The late element may be stronger than the cowpox ATI promoter in HeLa cells.

Poxviral vectors for low antibody response after a first priming immunization

Pr13.5 promoter for robust T-cell and antibody responses

The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.

Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

The invention is drawn to compositions and methods for the induction of a strong CD8 T cell response to a specific antigen(s). The combination of an early/late hybrid promoter directing strongly enhanced early expression of a neoantigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T cell epitope into the immunodominant epitope.

Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines

The present invention relates to a process for the preparation of &ggr;-linolenic acid (GLA) from Colpidium and its use in foodstuffs, cosmetics and pharmaceuticals. Colpidium can be fermentatively cultured up to a high absolute yield of GLA in an optimized medium.

Growing community of inventors

Munich, Germany

Kay Brinkmann